TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Routine Ultrasound Guidance for Vascular Access for Cardiac Procedures: a Randomized Trial
Brief Summary: A randomized, controlled trial to determine whether the use of ultrasound guidance for vascular access during coronary angiography or percutaneous coronary intervention (PCI) will reduce the rates of major vascular complications.


Options:
A: Arm Label: direct palpation; Type: ACTIVE_COMPARATOR; Interventions: Device: Direct Palpation-guided Radial Artery Catheter insertion | Arm Label: Ultrasound; Type: ACTIVE_COMPARATOR; Interventions: Device: Ultrasound-guided Radial Artery Catheter Insertion | Intervention Type: DEVICE; Name: Ultrasound-guided Radial Artery Catheter Insertion; Assigned to Arm(s): Ultrasound | Intervention Type: DEVICE; Name: Direct Palpation-guided Radial Artery Catheter insertion; Assigned to Arm(s): direct palpation
B: Arm Label: Palpation; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Palpation | Arm Label: Ultrasound; Type: EXPERIMENTAL; Interventions: Procedure: Ultrasound guidance | Intervention Type: PROCEDURE; Name: Ultrasound guidance; Assigned to Arm(s): Ultrasound | Intervention Type: PROCEDURE; Name: Palpation; Assigned to Arm(s): Palpation
C: Arm Label: Fluoroscopic + Ultrasound Guidance; Type: EXPERIMENTAL; Interventions: Procedure: Fluoroscopic + Ultrasound Guidance | Arm Label: Fluoroscopic Guidance Alone; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Fluoroscopic + Ultrasound Guidance; Assigned to Arm(s): Fluoroscopic + Ultrasound Guidance
D: Arm Label: Ultrasound radial artery catheter; Type: EXPERIMENTAL; Interventions: Procedure: Ultrasound guided radial artery catheterization. | Arm Label: Palpation based artery catheterization; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Blind insertion of radial artery catheterization | Intervention Type: PROCEDURE; Name: Ultrasound guided radial artery catheterization.; Assigned to Arm(s): Ultrasound radial artery catheter | Intervention Type: PROCEDURE; Name: Blind insertion of radial artery catheterization; Assigned to Arm(s): Palpation based artery catheterization

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Open-label, Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Tezacaftor in Combination With Ivacaftor in Subjects With Cystic Fibrosis Aged 6 Years and Older, Homozygous or Heterozygous for the F508del-CFTR Mutation
Brief Summary: This study evaluates the long-term safety and tolerability of tezacaftor in combination with ivacaftor (TEZ/IVA) in participants with cystic fibrosis (CF) aged 6 years and older, homozygous or heterozygous for the F508del mutation.


Options:
A: Arm Label: Part A; Type: EXPERIMENTAL; Interventions: Drug: lumacaftor, Drug: ivacaftor | Arm Label: Part B; Type: EXPERIMENTAL; Interventions: Drug: lumacaftor, Drug: ivacaftor | Intervention Type: DRUG; Name: lumacaftor; Assigned to Arm(s): Part A, Part B | Intervention Type: DRUG; Name: ivacaftor; Assigned to Arm(s): Part A, Part B
B: Arm Label: TEZ/IVA; Type: EXPERIMENTAL; Interventions: Drug: TEZ/IVA, Drug: IVA | Intervention Type: DRUG; Name: TEZ/IVA; Assigned to Arm(s): TEZ/IVA | Intervention Type: DRUG; Name: IVA; Assigned to Arm(s): TEZ/IVA
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: VX-661 Plus Ivacaftor Combination Placebo, Drug: Ivacaftor placebo | Arm Label: VX-661/IVA; Type: EXPERIMENTAL; Interventions: Drug: VX-661 Plus Ivacaftor Combination, Drug: Ivacaftor | Intervention Type: DRUG; Name: VX-661 Plus Ivacaftor Combination; Assigned to Arm(s): VX-661/IVA | Intervention Type: DRUG; Name: Ivacaftor; Assigned to Arm(s): VX-661/IVA | Intervention Type: DRUG; Name: VX-661 Plus Ivacaftor Combination Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Ivacaftor placebo; Assigned to Arm(s): Placebo
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 150 mg Ivacaftor q12h; Type: EXPERIMENTAL; Interventions: Drug: Ivacaftor | Intervention Type: DRUG; Name: Ivacaftor; Assigned to Arm(s): 150 mg Ivacaftor q12h | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Open-label, Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Tezacaftor in Combination With Ivacaftor in Subjects With Cystic Fibrosis Aged 6 Years and Older, Homozygous or Heterozygous for the F508del-CFTR Mutation
Brief Summary: This study evaluates the long-term safety and tolerability of tezacaftor in combination with ivacaftor (TEZ/IVA) in participants with cystic fibrosis (CF) aged 6 years and older, homozygous or heterozygous for the F508del mutation.


Options:
A: Arm Label: Part A: ELX/TEZ/IVA; Type: EXPERIMENTAL; Interventions: Drug: ELX/TEZ/IVA, Drug: IVA | Arm Label: Part B: ELX/TEZ/IVA; Type: EXPERIMENTAL; Interventions: Drug: ELX/TEZ/IVA, Drug: IVA | Intervention Type: DRUG; Name: ELX/TEZ/IVA; Assigned to Arm(s): Part A: ELX/TEZ/IVA, Part B: ELX/TEZ/IVA | Intervention Type: DRUG; Name: IVA; Assigned to Arm(s): Part A: ELX/TEZ/IVA, Part B: ELX/TEZ/IVA
B: Arm Label: TEZ/IVA; Type: EXPERIMENTAL; Interventions: Drug: TEZ/IVA, Drug: IVA | Intervention Type: DRUG; Name: TEZ/IVA; Assigned to Arm(s): TEZ/IVA | Intervention Type: DRUG; Name: IVA; Assigned to Arm(s): TEZ/IVA
C: Arm Label: Ataluren; Type: EXPERIMENTAL; Interventions: Drug: Ataluren | Intervention Type: DRUG; Name: Ataluren; Assigned to Arm(s): Ataluren
D: Arm Label: Ataluren; Type: EXPERIMENTAL; Interventions: Drug: Ataluren | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ataluren; Assigned to Arm(s): Ataluren | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Improving Adherence in Kidney Recipients: a Randomized Controlled Trial of a Post-transplant Education Intervention
Brief Summary: This study aims to test the effectiveness of an electronic-based video intervention and behavioral contract on improving medication adherence among kidney transplant recipients.


Options:
A: Arm Label: Video education + adherence contract; Type: EXPERIMENTAL; Interventions: Behavioral: Video education + adherence contract | Arm Label: Standard education; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Video education + adherence contract; Assigned to Arm(s): Video education + adherence contract
B: Arm Label: Telemetric Intervention Arm; Type: EXPERIMENTAL; Interventions: Behavioral: Telemetric Intervention | Arm Label: Standard of Care Arm; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Telemetric Intervention; Assigned to Arm(s): Telemetric Intervention Arm
C: Arm Label: Multi-component Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Action-focused problem-solving, Device: Electronic pillbox monitoring, dose reminders, and feedback | Arm Label: Attention control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Action-focused problem-solving; Assigned to Arm(s): Multi-component Intervention | Intervention Type: DEVICE; Name: Electronic pillbox monitoring, dose reminders, and feedback; Assigned to Arm(s): Multi-component Intervention
D: Arm Label: Patient education program; Type: EXPERIMENTAL; Interventions: Behavioral: Patient education program | Arm Label: Standard care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Patient education program; Assigned to Arm(s): Patient education program

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Reducing Suicide Risk Associated With Weight Loss
Brief Summary: The purpose of this study is to examine the efficacy of an intervention aimed at promoting a healthy lifestyle and reducing risk factors associated with eating pathology, nonsuicidal self-injury, and suicidal behavior. We are also interested in assessing whether this intervention has the potential to prevent future symptoms of eating problems and self-harm urges and behaviors. The broader goal of this research is to identify factors that may help us better understand the prevention of self-harm behaviors and develop more effective treatments for these problems.


Options:
A: Arm Label: Presence of SUD with BCBT; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive Behavioral Therapy | Arm Label: Presence of SUD with TAU; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Absence of SUD with BCBT; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive Behavioral Therapy | Arm Label: Absence of SUD with TAU; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Therapy; Assigned to Arm(s): Absence of SUD with BCBT, Presence of SUD with BCBT
B: Arm Label: Body Acceptance Program; Type: EXPERIMENTAL; Interventions: Behavioral: Body Acceptance Program | Arm Label: Waitlist control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Body Acceptance Program; Assigned to Arm(s): Body Acceptance Program
C: Intervention Type: DRUG; Name: Topiramate; Assigned to Arm(s): N/A
D: Arm Label: Group 1; Type: EXPERIMENTAL; Interventions: Device: Active tDCS, Device: Sham tDCS | Arm Label: Group 2; Type: EXPERIMENTAL; Interventions: Device: Active tDCS, Device: Sham tDCS | Intervention Type: DEVICE; Name: Active tDCS; Assigned to Arm(s): Group 1, Group 2 | Intervention Type: DEVICE; Name: Sham tDCS; Assigned to Arm(s): Group 1, Group 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Reducing Suicide Risk Associated With Weight Loss
Brief Summary: The purpose of this study is to examine the efficacy of an intervention aimed at promoting a healthy lifestyle and reducing risk factors associated with eating pathology, nonsuicidal self-injury, and suicidal behavior. We are also interested in assessing whether this intervention has the potential to prevent future symptoms of eating problems and self-harm urges and behaviors. The broader goal of this research is to identify factors that may help us better understand the prevention of self-harm behaviors and develop more effective treatments for these problems.


Options:
A: Arm Label: Experimental Arm; Type: EXPERIMENTAL; Interventions: Other: Other | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Other; Assigned to Arm(s): Experimental Arm
B: Arm Label: ASSIP plus SPP; Type: EXPERIMENTAL; Interventions: Behavioral: Attempted Suicide Short Intervention Program (ASSIP), Behavioral: Suicide Prevention Pathway (SPP) | Arm Label: CBT plus SPP; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive Behavioural Therapy (CBT), Behavioral: Suicide Prevention Pathway (SPP) | Arm Label: SPP alone; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Suicide Prevention Pathway (SPP) | Intervention Type: BEHAVIORAL; Name: Attempted Suicide Short Intervention Program (ASSIP); Assigned to Arm(s): ASSIP plus SPP | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioural Therapy (CBT); Assigned to Arm(s): CBT plus SPP | Intervention Type: BEHAVIORAL; Name: Suicide Prevention Pathway (SPP); Assigned to Arm(s): ASSIP plus SPP, CBT plus SPP, SPP alone
C: Arm Label: Body Acceptance Program; Type: EXPERIMENTAL; Interventions: Behavioral: Body Acceptance Program | Arm Label: Waitlist control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Body Acceptance Program; Assigned to Arm(s): Body Acceptance Program
D: Arm Label: Zolpidem-CR; Type: ACTIVE_COMPARATOR; Interventions: Drug: Zolpidem-CR | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Zolpidem-CR; Assigned to Arm(s): Zolpidem-CR | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Reducing Suicide Risk Associated With Weight Loss
Brief Summary: The purpose of this study is to examine the efficacy of an intervention aimed at promoting a healthy lifestyle and reducing risk factors associated with eating pathology, nonsuicidal self-injury, and suicidal behavior. We are also interested in assessing whether this intervention has the potential to prevent future symptoms of eating problems and self-harm urges and behaviors. The broader goal of this research is to identify factors that may help us better understand the prevention of self-harm behaviors and develop more effective treatments for these problems.


Options:
A: Arm Label: Body Acceptance Program; Type: EXPERIMENTAL; Interventions: Behavioral: Body Acceptance Program | Arm Label: Waitlist control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Body Acceptance Program; Assigned to Arm(s): Body Acceptance Program
B: Arm Label: No text messages; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Supportive and interactive text messages; Type: EXPERIMENTAL; Interventions: Other: Supportive and interactive text messages | Intervention Type: OTHER; Name: Supportive and interactive text messages; Assigned to Arm(s): Supportive and interactive text messages
C: Arm Label: brief intervention to prevent suicide attempt; Type: EXPERIMENTAL; Interventions: Behavioral: Brief intervention to prevent suicide attempt | Arm Label: standard of care; Type: OTHER; Interventions: Behavioral: Enhanced treatment as usual | Intervention Type: BEHAVIORAL; Name: Brief intervention to prevent suicide attempt; Assigned to Arm(s): brief intervention to prevent suicide attempt | Intervention Type: BEHAVIORAL; Name: Enhanced treatment as usual; Assigned to Arm(s): standard of care
D: Arm Label: Psychoeducational intervention (PEI); Type: EXPERIMENTAL; Interventions: Behavioral: Psychoeducational intervention (PEI) | Arm Label: Enhanced Treatment as Usual; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Enhanced treatment as usual (ETAU) | Intervention Type: BEHAVIORAL; Name: Psychoeducational intervention (PEI); Assigned to Arm(s): Psychoeducational intervention (PEI) | Intervention Type: BEHAVIORAL; Name: Enhanced treatment as usual (ETAU); Assigned to Arm(s): Enhanced Treatment as Usual

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Oral Nifedipine Versus Intravenous Magnesium Sulfate for Prevention of Preterm Labor in Symptomatic Placenta Previa: Randomized Controlled Trial.
Brief Summary: Antepartum hemorrhage is defined as bleeding from or within the female genital tract, occurring from 28+0 weeks of pregnancy and till delivery of the fetus. it occurs in 3-5% of pregnancies and is an important cause of perinatal and maternal morbidity and mortality worldwide


Options:
A: Intervention Type: DRUG; Name: Indomethacin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Magnesium sulfate; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: indomethacin; Assigned to Arm(s): N/A
C: Arm Label: Indomethacin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Indomethacin | Arm Label: Nifedipine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nifedipine | Intervention Type: DRUG; Name: Indomethacin; Assigned to Arm(s): Indomethacin | Intervention Type: DRUG; Name: Nifedipine; Assigned to Arm(s): Nifedipine
D: Arm Label: Nifidipne; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nifedipine | Arm Label: Magnisum sulphate; Type: EXPERIMENTAL; Interventions: Drug: Magnesium Sulfate | Intervention Type: DRUG; Name: Magnesium Sulfate; Assigned to Arm(s): Magnisum sulphate | Intervention Type: DRUG; Name: Nifedipine; Assigned to Arm(s): Nifidipne

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Cervical Pessary for Prevention of Spontaneous Preterm Birth in Singleton Pregnancies With Arrested Preterm Labor: a Randomized Controlled Trial
Brief Summary: Preterm birth (PTB) is a major cause of perinatal morbidity and mortality. Worldwide, about 15 million babies are born too soon every year, causing 1.1 million deaths, as well as short- and long-term disability in countless survivors.

Different strategies have been studied for prevention of spontaneous PTB (SPTB) in randomized controlled trials (RCTs), including progesterone, cerclage, cervical pessary, as well as lifestyle modification, such as smoking cessation, diet, aerobic exercise, and nutritional supplements. Most successful effort to reduce the incidence of SPTB have focused on asympatomatic women with risk factors, such as prior SPTB or short cervix. However, most SPTB occur in symptomatic women, i.e. women with preterm labor (PTL). Women with arrested PTL are at increased risk of SPTB.

The cervical pessary is a silicone device that has been used to prevent SPTB. The leading hypotheses for its mechanisms are two: that the pessary helps to keep the cervix closed, and that the pessary changes the inclination of the cervical canal so that the pregnancy weight is not directly above the internal os.

The aim of the study is to assess the efficacy of pessary in reducing preterm birth in women with arrested preterm labor


Options:
A: Arm Label: Pessary; Type: EXPERIMENTAL; Interventions: Device: arabin pessary | Arm Label: No Pessary; Type: ACTIVE_COMPARATOR; Interventions: Device: no pessary | Intervention Type: DEVICE; Name: arabin pessary; Assigned to Arm(s): Pessary | Intervention Type: DEVICE; Name: no pessary; Assigned to Arm(s): No Pessary
B: Arm Label: pessary; Type: EXPERIMENTAL; Interventions: Device: pessary | Arm Label: Progesterone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Progesterone | Intervention Type: DRUG; Name: Progesterone; Assigned to Arm(s): Progesterone | Intervention Type: DEVICE; Name: pessary; Assigned to Arm(s): pessary
C: Arm Label: Cervical Pessary; Type: EXPERIMENTAL; Interventions: Device: Cervical pessary | Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Cervical pessary; Assigned to Arm(s): Cervical Pessary
D: Arm Label: Pessary; Type: EXPERIMENTAL; Interventions: Device: Bioteque cup pessary | Arm Label: No pessary; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Bioteque cup pessary; Assigned to Arm(s): Pessary

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Active-controlled, Double-blinded, Double-dummy, Parallel-group, Multicenter Study to Investigate the Efficacy and Safety of Oral Molidustat in Comparison to Darbepoetin Alfa in Dialysis Subjects Treated With Erythropoiesis-Stimulating Agents (ESAs)
Brief Summary: The purpose of this study is to evaluate the efficacy and safety of molidustat in comparison to darbepoetin alfa in dialysis subjects with renal anemia who are treated with Erythropoiesis-Stimulating Agents (ESAs).


Options:
A: Arm Label: Molidustat group; Type: EXPERIMENTAL; Interventions: Drug: Molidustat (BAY85-3934), Drug: Placebo of Darbepoetin alfa | Arm Label: Darbepoetin alfa group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Darbepoetin alfa, Drug: Placebo of Molidustat (BAY85-3934) | Intervention Type: DRUG; Name: Molidustat (BAY85-3934); Assigned to Arm(s): Molidustat group | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): Darbepoetin alfa group | Intervention Type: DRUG; Name: Placebo of Molidustat (BAY85-3934); Assigned to Arm(s): Darbepoetin alfa group | Intervention Type: DRUG; Name: Placebo of Darbepoetin alfa; Assigned to Arm(s): Molidustat group
B: Arm Label: 0.5mg GSK1278863; Type: EXPERIMENTAL; Interventions: Drug: GSK1278863 | Arm Label: 2mg GSK1278863; Type: EXPERIMENTAL; Interventions: Drug: GSK1278863 | Arm Label: 5mg GSK1278863; Type: EXPERIMENTAL; Interventions: Drug: GSK1278863 | Arm Label: Placebo; Type: EXPERIMENTAL; Interventions: Other: Placebo | Intervention Type: DRUG; Name: GSK1278863; Assigned to Arm(s): 0.5mg GSK1278863, 2mg GSK1278863, 5mg GSK1278863 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: FG-4592; Type: EXPERIMENTAL; Interventions: Drug: FG-4592 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: FG-4592; Assigned to Arm(s): FG-4592 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: AKB-6548 240 mg; Type: EXPERIMENTAL; Interventions: Drug: AKB-6548 | Arm Label: AKB-6548 370 mg; Type: EXPERIMENTAL; Interventions: Drug: AKB-6548 | Arm Label: AKB-6548 500 mg; Type: EXPERIMENTAL; Interventions: Drug: AKB-6548 | Arm Label: AKB-6548 630 mg; Type: EXPERIMENTAL; Interventions: Drug: AKB-6548 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: AKB-6548; Assigned to Arm(s): AKB-6548 240 mg, AKB-6548 370 mg, AKB-6548 500 mg, AKB-6548 630 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A